Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab in Anterior Stroke with Large Ischemic Core Eligible for Endovascular Therapy
2023-509615-92-00Phase 2Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- May 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Glenzocimab arm with Placebo arm (2 arms). Primary endpoint: Functional outcome at 3 months. Started May 2024; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2023-509615-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509615-92-00.